Potent Anti-Viral Activity of a Trispecific HIV Antibody in SHIV-Infected Monkeys

Broadly neutralizing antibodies (bNAbs) represent an alternative to drug therapy for the treatment of HIV-1 infection. Immunotherapy with single bNAbs often leads to emergence of escape variants, suggesting a potential benefit of combination bNAb therapy. Here a trispecific bNAb is shown to reduce viremia 100- to 1000-fold in viremic SHIV-infected macaques. After treatment discontinuation, viremia rebounded transiently and returned to low levels, through CD8-mediated immune control. These viruses remained sensitive to the trispecific despite loss of sensitivity to one of the parental bNAbs. Similarly, the trispecific bNAb suppressed the emergence of resistance in viruses derived from HIV-1 infected subjects, in contrast to parental bNAbs. Trispecific HIV-1 antibodies therefore mediates potent antiviral activity in vivo that minimizes the potential for immune escape.

[1]  Allan C. deCamp,et al.  Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. , 2021, The New England journal of medicine.

[2]  B. Haynes,et al.  New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure , 2021, bioRxiv.

[3]  M. Nussenzweig,et al.  Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia , 2020, The Journal of experimental medicine.

[4]  A. Perelson,et al.  Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody , 2020, Proceedings of the National Academy of Sciences.

[5]  A. Perelson,et al.  Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo , 2020, Proceedings of the National Academy of Sciences.

[6]  Bertrand Z. Yeung,et al.  T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers , 2020, Nature Medicine.

[7]  R. Landovitz,et al.  Novel Antiretroviral Agents , 2020, Current HIV/AIDS Reports.

[8]  M. Nussenzweig,et al.  Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity , 2020, Nature Medicine.

[9]  Taina T. Immonen,et al.  Principles Governing Establishment versus Collapse of HIV-1 Cellular Spread. , 2019, Cell host & microbe.

[10]  Allan C. deCamp,et al.  Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study , 2019, PloS one.

[11]  Taina T. Immonen,et al.  Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes , 2019, PLoS pathogens.

[12]  M. Nussenzweig,et al.  Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic , 2019, Nature Medicine.

[13]  K. Foulds,et al.  OMIP‐052: An 18‐Color Panel for Measuring Th1, Th2, Th17, and Tfh Responses in Rhesus Macaques , 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[14]  Daniel W. Kulp,et al.  Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers , 2019, Immunity.

[15]  Daniel W. Kulp,et al.  Vaccine-induced protection from homologous Tier 2 simian-human immunodeficiency virus challenge in nonhuman primates , 2018 .

[16]  G. Raghu,et al.  SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) , 2018, European Respiratory Journal.

[17]  D. Burton,et al.  Recent progress in broadly neutralizing antibodies to HIV , 2018, Nature Immunology.

[18]  Nico Pfeifer,et al.  Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals , 2018, Nature Medicine.

[19]  Nico Pfeifer,et al.  Combination therapy with anti-HIV-1 antibodies maintains viral suppression , 2018, Nature.

[20]  S. Kent,et al.  Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies , 2018, Retrovirology.

[21]  J. Weiner,et al.  Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques , 2018, Journal of Virology.

[22]  S. Byrareddy,et al.  Follicular Dendritic Cells of Lymph Nodes as Human Immunodeficiency Virus/Simian Immunodeficiency Virus Reservoirs and Insights on Cervical Lymph Node , 2018, Front. Immunol..

[23]  L. Morris,et al.  HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies , 2018, PLoS pathogens.

[24]  J. Ananworanich,et al.  Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques , 2018, Journal of Virology.

[25]  R. Koup,et al.  New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment. , 2018, Annual review of medicine.

[26]  J. Mascola,et al.  Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults , 2018, PLoS medicine.

[27]  S. Fortune,et al.  Beyond binding: antibody effector functions in infectious diseases , 2017, Nature Reviews Immunology.

[28]  J. Mascola,et al.  Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial , 2017, PLoS medicine.

[29]  C. Beyrer,et al.  HIV Drug Resistance - An Emerging Threat to Epidemic Control. , 2017, The New England journal of medicine.

[30]  Mario Roederer,et al.  Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques , 2017, Science.

[31]  J. Mascola,et al.  Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys , 2017, Journal of Virology.

[32]  Anna Garbelli,et al.  How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher? , 2017, The Biochemical journal.

[33]  M. Nussenzweig,et al.  Early antibody therapy can induce long-lasting immunity to SHIV , 2017, Nature.

[34]  Ben Murrell,et al.  Antibody 10-1074 suppresses viremia in HIV-1-infected individuals , 2017, Nature Medicine.

[35]  N. Haigwood,et al.  Use of broadly neutralizing antibodies for HIV‐1 prevention , 2017, Immunological reviews.

[36]  Tongqing Zhou,et al.  Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. , 2016, Immunity.

[37]  J. Lifson,et al.  Defining HIV and SIV Reservoirs in Lymphoid Tissues , 2016, Pathogens & immunity.

[38]  G. Learn,et al.  Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques , 2016, Proceedings of the National Academy of Sciences.

[39]  A. Chakraborty,et al.  Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivo , 2016, Science.

[40]  B. Haynes,et al.  Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design , 2016, Journal of Virology.

[41]  Lynn Morris,et al.  Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection , 2016, PLoS pathogens.

[42]  J. Mascola,et al.  Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection , 2015, Science Translational Medicine.

[43]  J. Mascola,et al.  Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV‐1 human monoclonal antibody VRC01 in healthy adults , 2015, Clinical and experimental immunology.

[44]  J. Mascola,et al.  Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs , 2015, Journal of Virology.

[45]  J. Mascola,et al.  Activation and lysis of human CD4 cells latently infected with HIV-1 , 2015, Nature Communications.

[46]  Young Do Kwon,et al.  Crystal structure , conformational fixation , and entry-related interactions of mature ligand-free HIV-1 Env , 2016 .

[47]  Michael S. Seaman,et al.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.

[48]  Bette Korber,et al.  Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes , 2014, Journal of Virology.

[49]  John P. Moore,et al.  Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.

[50]  M. Nussenzweig,et al.  Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity , 2014, Cell.

[51]  Young Do Kwon,et al.  Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo , 2014, Journal of Virology.

[52]  J. Hoxie,et al.  Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor , 2014, Science Translational Medicine.

[53]  T. Greenough,et al.  A Novel Assay for Antibody-Dependent Cell-Mediated Cytotoxicity against HIV-1- or SIV-Infected Cells Reveals Incomplete Overlap with Antibodies Measured by Neutralization and Binding Assays , 2012, Journal of Virology.

[54]  D. Irvine,et al.  A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.

[55]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[56]  Alan S. Perelson,et al.  Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1 , 2009, The Journal of experimental medicine.

[57]  David C Montefiori,et al.  Measuring HIV neutralization in a luciferase reporter gene assay. , 2009, Methods in molecular biology.

[58]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[59]  K. Crandall,et al.  Characterization of the Follicular Dendritic Cell Reservoir of Human Immunodeficiency Virus Type 1 , 2008, Journal of Virology.

[60]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[61]  A. McPherson,et al.  Atomic Force Microscopy Investigation of Human Immunodeficiency Virus (HIV) and HIV-Infected Lymphocytes , 2003, Journal of Virology.

[62]  H. Ochs,et al.  The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. , 1988, The Journal of laboratory and clinical medicine.